PBC失代偿肝硬化患者潜在肝脏再代偿标准的评估
该回顾性研究纳入42例首次失代偿的PBC肝硬化患者,探索UDCA生化应答(Paris-II标准)作为病因治疗替代指标下的再代偿可能。7例(16.7%)实现再代偿,再代偿与较低MELD-Na、胆红素、ALP及静脉曲张出血事件相关;UDCA应答者再代偿率41.7%高于无应答者9.5%。再代偿后仍可发生肝脏相关并发症,需密切随访。
要点
- PBC失代偿肝硬化患者经UDCA治疗可能实现肝脏再代偿,本队列再代偿率为16.7%。
- UDCA应答(Paris-II标准)者再代偿率41.7%,无应答者9.5%。
- 再代偿后仍可出现肝脏恶性肿瘤和/或门静脉血栓等并发症,需密切随访。
核心结论
- PBC失代偿肝硬化患者在UDCA治疗下可能实现肝脏再代偿。
- 再代偿后仍可发生肝脏相关并发症,患者应保持密切随访。
研究设计与样本
- 回顾性纳入首次失代偿的PBC肝硬化患者42例,年龄63.5(IQR 51.9-69.2)岁,女性88.1%,MELD-Na 13.5(IQR 11.0-15.0)。
- 失代偿后随访41.9(IQR 11.0-70.9)个月。
- 再代偿定义为腹水和肝性脑病缓解且停用利尿/HE治疗、无静脉曲张出血及持续肝功能改善。
主要发现
- 7例(16.7%)实现再代偿。
- 再代偿与较低MELD-Na(SHR 0.90;p=0.047)、较低胆红素(SHR每mg/dL 0.44;p=0.005)和较低ALP(SHR每10 U/L 0.67;p=0.001)相关。
- 静脉曲张出血作为失代偿事件与再代偿概率相关(SHR 4.37;p=0.069)。
- 33例UDCA治疗≥1年,12例(36%)达到Paris-II应答标准;应答者再代偿5/12(41.7%),无应答者2/21(9.5%)。
- 再代偿与无移植生存数值上改善相关(HR 0.46;p=0.335)。
关键数值与推荐
- UDCA生化应答采用Paris-II标准作为成功病因治疗的替代指标。
- 再代偿定义包括腹水和HE缓解且停用相应治疗、无静脉曲张出血及持续肝功能改善。
临床怎么用
- 对PBC失代偿肝硬化患者,UDCA治疗下可评估再代偿可能。
- UDCA应答(Paris-II标准)与更高再代偿概率相关,可作为评估参考。
- 再代偿后仍需密切随访,警惕肝脏恶性肿瘤和门静脉血栓等并发症。
局限性
- 回顾性研究设计。
- 样本量较小(42例)。
- 再代偿与无移植生存关联的p值未达统计学显著性(p=0.335)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aetiological therapy improves liver function and may enable hepatic recompensation in decompensated cirrhosis. AIMS: We explored the potential for recompensation in patients with decompensated primary biliary cholangitis (PBC) - considering a biochemical response to ursodeoxycholic acid (UDCA) according to Paris-II criteria as a surrogate for successful aetiological treatment. METHODS: Patients with PBC were retrospectively included at the time of first decompensation. Recompensation was defined as (i) resolution of ascites and hepatic encephalopathy (HE) despite discontinuation of diuretic/HE therapy, (ii) absence of variceal bleeding and (iii) sustained liver function improvement. RESULTS: In total, 42 patients with PBC with decompensated cirrhosis (age: 63.5 [IQR: 51.9-69.2] years; 88.1% female; MELD-Na: 13.5 [IQR: 11.0-15.0]) were included and followed for 41.9 (IQR: 11.0-70.9) months after decompensation. Seven patients (16.7%) achieved recompensation. Lower MELD-Na (subdistribution hazard ratio [SHR]: 0.90; p = 0.047), bilirubin (SHR per mg/dL: 0.44; p = 0.005) and alkaline phosphatase (SHR per 10 U/L: 0.67; p = 0.001) at decompensation, as well as variceal bleeding as decompensating event (SHR: 4.37; p = 0.069), were linked to a higher probability of recompensation. Overall, 33 patients were treated with UDCA for ≥1 year and 12 (36%) achieved Paris-II response criteria. Recompensation occurred in 5/12 (41.7%) and in 2/21 (9.5%) patients with vs. without UDCA response at 1 year, respectively. Recompensation was linked to a numerically improved transplant-free survival (HR: 0.46; p = 0.335). Nonetheless, 4/7 recompensated patients presented with liver-related complications after developing hepatic malignancy and/or portal vein thrombosis and 2 eventually died. CONCLUSIONS: Patients with PBC and decompensated cirrhosis may achieve hepatic recompensation under UDCA therapy. However, since liver-related complications still occur after recompensation, patients should remain under close follow-up.
引用
- Hofer BS, Burghart L, Halilbasic E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther. 2024. PMID: 38409879. doi:10.1111/apt.17908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。